GSK Embraces PARP Promise With Tesaro Buy

 
• By Kevin Grogan

The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.

Climbing wall
GSK clambers back into oncology • Source: Shutterstock

More from Deals

More from Business